MagicRNA

Based in Guangdong, China, and founded in 2021, Shenzhen MagicRNA Biotech Co. , Ltd. , trading as MagicRNA, operates as a biotechnology company dedicated to developing RNA drugs. It has applied for more than ten invention patents, including multiple PCT and European and American invention patents, of which 4 patents have been authorized.

The company cooperated with Sun Yat-sen University Affiliated Hospital, West China Hospital, and other hospitals in the fields of urology, gynecological oncology, and other fields. In August 2026, MagicRNA raised a Series B funding co-led by China International Capital Corporation and Kangjun Capital, with participation from China Development Bank Capital, Boc Private Equity Firm, SND Ventures Group, Guoshun Investment, IDG Capital, Nanling Fund, Huatai Zijin Investment, Sino Biopharmaceutical Limited and Goldport Capital. The company engages in the R&D of mRNA drugs for gynecological diseases and urinary system tumors, based on the self-development of three technology platforms, including the mRNA sequence design platform, the mRNA synthesis platform, and the lipid nanoparticles (LNP) delivery platform. The company has product lines such as infectious disease mRNA vaccines, mRNA tumor vaccines, and protein replacement therapies.

Magic RNA developed Engineered Cell Targeted LNPs (EnC-LNPs) platform, which provides solutions for extrahepatic delivery of nucleic acid drugs. The company's first tumor therapeutic drug, HN2201, has completed preclinical development. The company's revenue is generated by providing mRNA and circular RNA products, custom mRNA synthesis, and LNP encapsulation services to biotech and pharmaceutical clients. Following the Series B funding raised in August 2026, the company will further solidify its leading position in the in vivo CAR-T industry and accelerate the IND application, global clinical development, and business cooperation for HN2301 in China and the United States.